Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-25-068845
Filing Date
2025-03-31
Accepted
2025-03-31 16:57:24
Documents
14
Period of Report
2025-03-25
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A d924652d8ka.htm   iXBRL 8-K/A 26146
2 EX-99.1 d924652dex991.htm EX-99.1 81544
  Complete submission text file 0001193125-25-068845.txt   242786

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA whwk-20250325.xsd EX-101.SCH 2841
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE whwk-20250325_lab.xml EX-101.LAB 18701
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE whwk-20250325_pre.xml EX-101.PRE 11689
16 EXTRACTED XBRL INSTANCE DOCUMENT d924652d8ka_htm.xml XML 4309
Mailing Address 2 HEADQUARTERS PLAZA EAST BUILDING, 11TH FLOOR MORRISTOWN NJ 07960
Business Address 2 HEADQUARTERS PLAZA EAST BUILDING, 11TH FLOOR MORRISTOWN NJ 07960 551-321-2234
Whitehawk Therapeutics, Inc. (Filer) CIK: 0001422142 (see all company filings)

EIN.: 611547850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-38560 | Film No.: 25794515
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)